ClinicalTrials.gg
RecruitingNCT07205289Updated Oct 3, 2025

Serum Collection Study for Assay Development

A Phase 1 interventional study of Gamma-PN in Pneumococcal Disease, Invasive and Pneumococcal Disease, sponsored by GPN Vaccines. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by GPN Vaccines · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.

Planned enrollment
16th of 16
12 · median 851
Started
2025
with 1 other
Phase 1
3 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
3 of 16
GPN Vaccines

Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 16th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 15th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pneumococcal Infections with a site in Australia, or all of them as a file.
02

Study summary

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

Read the detailed description

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

Participants will receive a dose of Gamma-PN and serum will be collected pre dose and Day 28

03

Conditions studied

  • Pneumococcal Disease, Invasive
  • Pneumococcal Disease

Keywords

  • Vaccination pneumococcal
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • good general health

Exclusion criteria

Exclusion Criteria:

  • no previous pneumococcal vaccine
05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Gamma -PN

    Intramuscular administration 500 mcg

    Biological: Gamma-PN

Interventions

  • BiologicalGamma-PN

    Killed whole-cell pneumococcal vaccine

06

What researchers measure

Primary outcomes

  1. OPA

    Opsonophagocytic assay

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • University of Adelaide Clinical Research Facility
    Adelaide, South Australia 5000, Australia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jan 2026, 3 months later.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 3, 2025
StartEst.
Oct 2025
Primary completionEst.
Jan 2026
CompletionEst.
Jun 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07205289
Lead sponsor
GPN Vaccines
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Oct 2025 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Oct 3, 2025

Study contacts

Nerissa Lakhan, PhD
Contact
nerissa@gpnvaccines.com
+61-432 161 783
Paul E Rolan, MD
Contact
paul@gpnvaccines.com
+61-405 670 420
Eve Kennedy, PhD
study director · GPN Vaccines Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion